ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3002-East-Melbourne-Epworth-Freemasons
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
28
trial(s) found.
NCT07291076
Advanced
Phase 1 / Phase 2
Not yet recruiting
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (
CA266-0006
)
anti-CTLA4 monoclonal antibody
bispecific PD-L1/VEGFA antibody
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4560 - Nambour - Nambour General Hospital
NCT07115043
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors (
D7350C00001
)
CD8-guided IL-2 candidate
Cancer
Clear cell renal cell carcinoma
Gastric cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Merkel cell carcinoma
Non-small cell lung cancer
Squamous cell carcinoma
Triple-negative breast cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT07101328
Haem
Phase 1
Not yet recruiting
BAF-FRontier-1
, A First-in-Human, Phase 1a/1b Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies
B-cell lymphoma
Burkitt lymphoma
Leukaemia
Lymphoma
Waldenström Macroglobulinaemia
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06989112
Advanced
Phase 3
Recruiting
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer (
DE-01
)
anti-ERBB2 antibody-drug conjugate
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Endometrial cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06952504
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (
TroFuse-033
/GOG-3119/ENGOT-en29)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Endometrial cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06879041
Advanced
Phase 1
Recruiting
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer (
D7580C00001
)
radioligand,PSMA-targeting
Castrate-resistant prostate cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06824467
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103) (
2870-022
)
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
Fallopian tube cancer
Ovarian cancer
Primary peritoneal serous carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
NCT06806033
Haem
Phase 2
Recruiting
A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (
GO45434
)
antimetabolite
bispecific T-cell engager,CD20-targeting
platinum-based antineoplastic agent
Diffuse large B-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06492304
Haem
Phase 1
Recruiting
A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (
CRSP-ONC-008
)
allogeneic CAR-T-cell therapy,CD70-targeting
Acute myeloid leukaemia
B-cell lymphoma
T-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06450106
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy (
STM-416p-201
)
Prostate cancer
VIC
3002 - East Melbourne - Epworth Freemasons
3051 - Melbourne - Australian Prostate Centre
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06267729
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer:
APOLLO
allogeneic CAR-T-cell therapy,STEAP2-targeting
Prostate cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06215118
Haem
Phase 1
Recruiting
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (
MagnetisMM-30--C1071030
)
CELMoD agent
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
3121 - Richmond - Epworth Freemasons Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT06188520
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (
CYCAD-1
)
CDK2 inhibitor
Breast cancer
High-grade serous ovarian cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06007690
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (
CoMpass
)
viral nanoparticle drug conjugates
Choroidal melanoma
Uveal melanoma
VIC
3002 - East Melbourne - Epworth Freemasons
NA
NA
NCT05827081
Curative
Phase 3
Recruiting
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) (
Adjuvant-WIDER
)
CDK4/6 inhibitor
Breast cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3168 - Clayton - Monash Medical Centre
NCT05552976
Haem
Phase 3
Recruiting
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-2
cereblon E3 ligase modulator
glucocorticoid
proteasome inhibitor
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05279300
Advanced
Phase 1
Recruiting
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination With Systemic Therapies in Patients With Advanced Solid Tumors and Lymphomas (
CS5001-101
)
anti-ROR1 antibody-drug conjugate
Lymphoma
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide (TERMINATED)
NCT05128825
Advanced
Phase 2
Recruiting
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (
DENALI
/ ZN-c3-005 / GOG-3066)
WEE1 inhibitor
High-grade serous ovarian cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5065 - Toorak Gardens - Burnside War Memorial Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05094336
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors (
MTAPESTRY-101
)
PRMT5 inhibitor,MTA-co-operative
taxane
Gastric cancer
Gastroesophageal cancer
NOT Central nervous system cancer
Pancreatic adenocarcinoma
Squamous non-small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3002 - East Melbourne - Epworth Freemasons
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05091424
Haem
Phase 1
Recruiting
A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (
BO43243
)
Bcl2 inhibitor
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05020236
Haem
Phase 3
Recruiting
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR (
MAGNETISMM-5
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03093116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (
TRIDENT-1
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse (COMPLETED)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)
3002 - East Melbourne - Epworth Freemasons (COMPLETED)
SA
5042 - Bedford Park - Flinders Medical Centre (COMPLETED)
ACTRN12615001031550
Radonc
Phase 2
Recruiting
A Phase II Study for the Treatment of Localised Spine Metastasis: Assessing the Safety and Efficacy of Image Guided Radiosurgery prior to Surgical Stabilisation. (
LASERS
)
Radiotherapy
cancer therapy
Cancer
VIC
3002 - East Melbourne - Epworth Freemasons
3121 - Richmond - Epworth Freemasons Hospital
NCT07000149
Advanced
Phase 3
Active not recruiting
A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (
eVOLVE-RCC02
)
HIF2a inhibitor
anti-CTLA4 monoclonal antibody
anti-PD-1 monoclonal antibody
bispecific PD-L1/CTLA4 antibody
Clear cell renal cell carcinoma
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4032 - Chermside - Icon Cancer Care Chermside
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05317416
Haem
Phase 3
Active not recruiting
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION (
MagnetisMM-7
)
bispecific T-cell engager,BCMA-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4217 - Benowa - Pindara Private Hospital
NA
NA
NCT03900442
Advanced
Phase 1
Unknown status
Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies (
PTX-100-PD-012017
)
geranylgeranyl transferase inhibitor
Colorectal cancer
Gastric cancer
Multiple myeloma
Pancreatic adenocarcinoma
Peripheral T-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (23)
Not yet recruiting (2)
Active not recruiting (2)
Unknown status (1)
Recruitment Country and State
VIC (27)
NSW (12)
QLD (11)
WA (6)
SA (5)
NT (1)
TAS (1)
NZ (1)
Phase
Phase 1 (8)
Phase 1 / Phase 2 (7)
Phase 2 (4)
Phase 3 (9)
Trial Type
Advanced (18)
Haem (8)
Curative (1)
Radonc (1)
Cancer Therapy Class
PD-1/PD-L1
25%
PD-1
18%
cereblon
14%
CTLA4
11%
PD-L1
11%
VEGF
11%
Trop2
11%
CD20
11%
BCMA
11%
TIGIT
7%
CDK4
7%
CDK6
7%
oestrogen axis
7%
VEGFA
4%
ERBB2
4%
PSMA
4%
CD70
4%
STEAP2
4%
CDK2
4%
ER
4%
GnRH
4%
androgen axis
4%
proteasome
4%
ROR1
4%
WEE1
4%
PRMT5
4%
Bcl2
4%
IL-6
4%
CD38
4%
ALK
4%
ROS1
4%
TRK
4%
HIF2a
4%
geranylgeranyl transferase
4%
Facility
3002 - East Melbourne - Epworth Freemasons (28)
2050 - Camperdown - Chris O'Brien Lifehouse (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
3121 - Richmond - Epworth Freemasons Hospital (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
NA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
3004 - Melbourne, Southbank - Alfred Health (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
4120 - Greenslopes - Greenslopes Private Hospital (2)
2500 - Wollongong - Wollongong Hospital (2)
3168 - Clayton - Monash Medical Centre (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
4032 - Chermside - Icon Cancer Care Chermside (2)
3066 - Epping - Northern Hospital (2)
4217 - Benowa - Pindara Private Hospital (2)
4560 - Nambour - Nambour General Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
3051 - Melbourne - Australian Prostate Centre (1)
6009 - Nedlands - One Clinical Research (1)
2170 - Liverpool - Liverpool Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
2541 - Nowra - Shoalhaven District Memorial Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Gastrointestinal cancer
Gynaecological cancer
Lymphoma
Upper gastrointestinal cancer
Urogenital cancer
Non-Hodgkin's lymphoma
Multiple myeloma
Plasma cell disorder
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
B-cell lymphoma
B-cell malignancy
Mature B-cell malignancy
Breast cancer
Epithelial Ovarian Cancer
Gastric cancer
Gastroesophageal cancer
High-grade serous ovarian cancer
Lung cancer
Non-small cell lung cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Respiratory tract cancer
Thoracic cancer
Leukaemia
Male genital cancers
Prostate cancer
Colorectal cancer
Lower gastrointestinal cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Hepatobiliary cancer
Clear cell renal cell carcinoma
Kidney cancer
Melanoma
High-grade B-cell lymphoma
Endometrial cancer
Fallopian tube cancer
Peritoneal cancer
Primary peritoneal serous carcinoma
T-cell lymphoma
Hepatocellular carcinoma
Breast adenocarcinoma
Carcinoma
Head and neck cancer
Head and neck squamous cell carcinoma
Merkel cell carcinoma
Non-melanoma skin cancer
Skin cancer
Squamous cell carcinoma
Triple-negative breast cancer
Burkitt lymphoma
Waldenström Macroglobulinaemia
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Diffuse large B-cell lymphoma
Acute myeloid leukaemia
Myeloid leukaemia
Biliary tract cancer
Choroidal melanoma
Uveal melanoma
Primary fallopian tube serous carcinoma
Squamous non-small-cell lung cancer
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Small lymphocytic lymphoma
Peripheral T-cell lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy